NICE backs skin cancer drug Libtayo for NHS use

2 July 2019
sanofi_france_large

National Health Service patients in the UK will be the first to gain access in Europe to new skin cancer treatment, Libtayo (cemiplimab), through the Cancer Drugs Fund (CDF), it was revealed today, just a day after the drug won conditional regulatory approval from the European Commission.

French pharma major Sanofi (Euronext: SAN), which has developed the product in partnership with US biotech Regeneron Pharmaceuticals (Nasdaq: REGN), today announced that the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination (FAD) recommending Libtayo as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults when curative surgery or curative radiation is not appropriate.

According to a Sanofi statement:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology